COMP <GO>
ACAD vs LLY // EV/EBITDA & P/E VALUATION
ACADIA Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ACAD 5
— LLY 8
▲ EV/EBITDA & P/E VALUATION LEADER: ACAD
LAST: $20.76 (+2.17%) • MKT CAP: $3.58B
valuation
31.2x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACAD | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 91.70% | 83.64% | +8.06 | ACAD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.90% | 32.36% | -24.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 31.2x | 36.4x | -5.22 | ACAD | /valuation <GO> |
| Free Cash Flow Yield | 2.94% | 2.30% | +0.64 | ACAD | /fcf-yield <GO> |
| Operating Margin | 9.80% | 40.21% | -30.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 36.50% | 31.90% | +4.60 | ACAD | /net-margins <GO> |
| Revenue Growth (YoY) | 11.90% | 45.51% | -33.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.26 | 9.29 | -3.03 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 66.6 | -21.08 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 26.3x | -17.75 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.58B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACAD REV | LLY REV | ACAD GROSS % | LLY GROSS % | ACAD FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.07B | $65.18B | 91.7% | 83.0% | $105.1M | $16.81B |
| FY 2024 | $957.8M | $45.04B | 91.5% | 81.3% | $157.2M | $8.82B |
| FY 2023 | $726.4M | $34.12B | — | 79.3% | $16.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
LLY // BETA 0.51